Differential effects of advanced glycation end-products on renal tubular cell inflammation

Nephrology

Volumn 16, Issue 4, 2011, Pages 417-425

  Tang, Sydney C W ^a   Chan, Loretta Y Y ^a   Leung, Joseph C K ^a   Cheng, Amy S ^a   Lin, Miao ^a   Lan, Hui Y ^a   Lai, Kar N ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

advanced glycation end products; carboxymethyllysine albumin; chemokines; diabetic nephropathy; proximal tubular cells

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CONNECTIVE TISSUE GROWTH FACTOR; GLYCOSYLATED ALBUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METHYLGLYOXAL; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; NEPHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CHEMOKINE CCL2; CONNECTIVE TISSUE GROWTH FACTOR; EPITHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; KIDNEY TUBULES, PROXIMAL; LYSINE; NEPHRITIS, INTERSTITIAL; NF-KAPPA B; PYRUVALDEHYDE; RECEPTORS, IMMUNOLOGIC; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955420320     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01437.x     Document Type: Article

References (24)

1. Zimmet P, Alberti KG, Shaw J,. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7. (Pubitemid 34000780)
2. Mainous AG, III, Baker R, Koopman RJ, et al,. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way. Diabetologia 2007; 50: 934-40. (Pubitemid 46559242)
3. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI,. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-51. (Pubitemid 24230711)
4. Tang SC, Leung JC, Chan LY, Tsang AW, Lai KN,. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-{gamma} agonist. J. Am. Soc. Nephrol. 2006; 17: 1633-43. (Pubitemid 43794666)
5. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH,. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006; 69: 73-80. (Pubitemid 43117741)
6. Morcos M, Sayed AA, Bierhaus A, et al,. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002; 51: 3532-44. (Pubitemid 35403461)
7. Stenvinkel P, Ketteler M, Johnson RJ, et al,. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005; 67: 1216-33. (Pubitemid 40463099)
8. Tashiro K, Koyanagi I, Saitoh A, et al,. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 2002; 16: 1-4.
9. Tang S, Leung JC, Abe K, et al,. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J. Clin. Invest. 2003; 111: 515-27. (Pubitemid 36228009)
10. Singh R, Barden A, Mori T, Beilin L,. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-46. (Pubitemid 32156196)
11. Tang SC, Chan LY, Leung JC, et al,. Bradykinin and high glucose promote renal tubular inflammation. Nephrol. Dial. Transplant. 2010; 25: 698-710.
12. Gerritsma JS, van KC, Gerritsen AF, van Es LA, Daha MR,. Transforming growth factor-beta 1 regulates chemokine and complement production by human proximal tubular epithelial cells. Kidney Int. 1998; 53: 609-16. (Pubitemid 28124274)
13. Schiekofer S, Andrassy M, Chen J, et al,. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003; 52: 621-33. (Pubitemid 36323567)
14. Goldin A, Beckman JA, Schmidt AM, Creager MA,. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605. (Pubitemid 44199649)
15. Li J, Schmidt AM,. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 1997; 272: 16498-506. (Pubitemid 27276477)
16. Oldfield MD, Bach LA, Forbes JM, et al,. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 2001; 108: 1853-63. (Pubitemid 34015131)
17. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A,. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32. (Pubitemid 16095602)
18. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G,. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-34.
19. Edelstein D, Brownlee M,. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-9.
20. Degenhardt TP, Alderson NL, Arrington DD, et al,. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002; 61: 939-50. (Pubitemid 34175462)
21. Thomas MC, Tikellis C, Burns WM, et al,. Interactions between renin angiotensin system and advanced glycation in the kidney. J. Am. Soc. Nephrol. 2005; 16: 2976-84. (Pubitemid 44743495)
22. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB,. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 2007; 27: 605-14. (Pubitemid 350014947)
23. Li JH, Wang W, Huang XR, et al,. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 2004; 164: 1389-97. (Pubitemid 38387804)
24. Li JH, Huang XR, Zhu HJ, et al,. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. 2004; 18: 176-8.